Castleark Management Portfolio holdings
CastleArk Management is an employee-owned manager of growth stock strategies, founded in 1999. It mainly buys U.S. stocks and, to a lesser extent, those of other countries, and its process aims to exploit behavioral biases found in growth stocks. Co-founder Jerome Castellini controls it and a sister firm, CastleArk Alternatives, which has existed since 2005 and sponsors private funds. Its clients are mainly investment funds and institutions, many of them retirement plans.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Morgan Stanley
MS
|
+$36.6M |
| 2 |
Apple
AAPL
|
+$34.9M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$32.1M |
| 4 |
Visa
V
|
+$26.4M |
| 5 |
Gilead Sciences
GILD
|
+$24.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Charles Schwab
SCHW
|
+$45.1M |
| 2 |
Ulta Beauty
ULTA
|
+$26.5M |
| 3 |
Shopify
SHOP
|
+$25.5M |
| 4 |
Chevron
CVX
|
+$23.2M |
| 5 |
DigitalOcean
DOCN
|
+$19.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.63% |
| 2 | Industrials | 12.24% |
| 3 | Miscellaneous | 11.82% |
| 4 | Healthcare | 10.33% |
| 5 | Consumer Discretionary | 9.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Uber
UBER
$136B
| $13.7M | 0.37% |
189,417
+19,541
| +12% | +$1.43M |
2025 Q2
4 quarters
|
|
52
Ultra Clean Holdings
UCTT
$2.25B
| $13.7M | 0.37% |
95,770
-4,360
| -4% | -$384K |
2026 Q1
1 quarter
|
|
53
Novanta
NOVT
$5.53B
| $13.5M | 0.36% |
83,190
+48,200
| +138% | +$6.97M |
2026 Q1
1 quarter
|
|
54
Axon Enterprise
AXON
$34.6B
| $13.1M | 0.35% |
23,423
+14,562
| +164% | +$6.09M |
2022 Q3
15 quarters
|
|
55
Boeing
BA
$139B
| $12.9M | 0.35% |
59,520
+33,440
| +128% | +$7.44M |
2013 Q2
52 quarters
|
|
56
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $12.8M | 0.35% |
80,890
| – | – |
2025 Q3
3 quarters
|
|
57
Element Solutions
ESI
$8.32B
| $12.6M | 0.34% |
263,644
-10,240
| -4% | -$425K |
2023 Q3
11 quarters
|
|
58
MYR Group
MYRG
$4.33B
| $12.5M | 0.34% |
24,920
+7,360
| +42% | +$3.02M |
2026 Q1
1 quarter
|
|
59
Guardant Health
GH
$22.9B
| $12M | 0.32% |
80,293
-79,990
| -50% | -$8.7M |
2025 Q2
4 quarters
|
|
60
iShares 20+ Year Treasury Bond ETF
TLT
$47.6B
| $11.9M | 0.32% |
137,270
| – | – |
2024 Q4
6 quarters
|
|
61
JFrog
FROG
$10.5B
| $11.8M | 0.32% |
129,480
+36,650
| +39% | +$2.38M |
2026 Q1
1 quarter
|
|
62
Citigroup
C
$204B
| $11.7M | 0.32% |
83,734
+36,250
| +76% | +$4.72M |
2013 Q2
52 quarters
|
|
63
XPO
XPO
$22.3B
| $11.7M | 0.32% |
57,079
+31,230
| +121% | +$6.61M |
2023 Q2
12 quarters
|
|
64
Kulicke & Soffa
KLIC
$3.73B
| $11.6M | 0.31% |
86,950
-19,430
| -18% | -$1.9M |
2026 Q1
1 quarter
|
|
65
HealthEquity
HQY
$8.58B
| $11.5M | 0.31% |
127,770
+79,260
| +163% | +$6.72M |
2026 Q1
1 quarter
|
|
66
Xometry
XMTR
$5.47B
| $11.3M | 0.31% |
117,518
+62,750
| +115% | +$4.48M |
2025 Q2
4 quarters
|
|
67
Lattice Semiconductor
LSCC
$13.6B
| $11.3M | 0.31% |
73,979
-17,660
| -19% | -$2.28M |
2025 Q1
5 quarters
|
|
68
Jazz Pharmaceuticals
JAZZ
$13.9B
| $11.3M | 0.3% |
46,920
-1,820
| -4% | -$399K |
2026 Q1
1 quarter
|
|
69
Helios Technologies
HLIO
$2.22B
| $11.2M | 0.3% |
125,409
-35,000
| -22% | -$2.69M |
2025 Q3
3 quarters
|
|
70
Kiniksa Pharmaceuticals
KNSA
$7.13B
| $11.1M | 0.3% |
174,032
-7,480
| -4% | -$388K |
2025 Q3
3 quarters
|
|
71
ESCO Technologies
ESE
$6.25B
| $11.1M | 0.3% |
31,572
+13,720
| +77% | +$4.29M |
2025 Q2
4 quarters
|
|
72
VSE Corp
VSEC
$4.5B
| $11M | 0.3% |
48,216
-1,870
| -4% | -$359K |
2024 Q4
6 quarters
|
|
73
Timken Company
TKR
$7.87B
| $11M | 0.3% |
75,400
+35,010
| +87% | +$4.21M |
2026 Q1
1 quarter
|
|
74
Hexcel
HXL
$6.15B
| $10.6M | 0.29% |
+106,050
| New | +$9.6M |
2026 Q2
0 quarters
|
|
75
BorgWarner
BWA
$10.4B
| $10.5M | 0.28% |
158,726
+10,220
| +7% | +$647K |
2025 Q2
4 quarters
|
|
Similar funds
Castleark Management's Q2 2026 Portfolio in Review
As of Q2 2026, Castleark Management held 350 positions worth $3.71B, up 23% from $3.02B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Castleark Management's Q2 2026 filing shows 58 new, 69 increased, 89 reduced and 41 closed positions. Its largest new stake was SharkNinja: 127,170 shares worth $19.4M. The largest sale was Charles Schwab, an estimated $45.1M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 32% a quarter earlier, followed by Industrials and Miscellaneous.
- Castleark Management's largest Q2 2026 buy was SharkNinja: 127,170 shares worth $19.4M.
- Castleark Management added most to Morgan Stanley in Q2 2026, an estimated $36.6M increase.
- Castleark Management's biggest Q2 2026 reduction was Charles Schwab, cutting an estimated $45.1M.
- Castleark Management fully exited Ulta Beauty in Q2 2026, selling an estimated $26.5M.
- Castleark Management's ten largest holdings make up 34% of its $3.71B portfolio in Q2 2026.
- Castleark Management opened 58 new positions and closed 41 in Q2 2026.
- Castleark Management's portfolio value rose 23% quarter-over-quarter to $3.71B.
Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.